Skip to main content
Figure 3 | Genetic Vaccines and Therapy

Figure 3

From: AAV2-mediated in vivo immune gene therapy of solid tumours

Figure 3

Immune therapy of tumours in vivo. (a-b) Effect of AAV2 delivered GM-CSF, B7-1 on SC JBS fibrosarcoma growth in vivo. (a) Representative growth curve of JBS tumours treated with AAV2-GB particles or null vector (AAV2-Luc) or untreated. There was a significant difference (p vs. null vector = 0.028, vs. untreated = 0.017) in tumour volume at day 21 between the tumours transduced with AAV2-GB and control tumours. (b) Approximately 66% animals treated with AAV2-GB survived 100 days post treatment, with no signs of tumour recurrence. Treatment with null vector resulted in a slight improvement in survival, but this did not approach significance. (c-d) Effect of AAV2 delivered GM-CSF, B7-1 on SC LLC tumour growth in vivo. Established LLC tumours were treated by IT administration of AAV2-GB or AAV-MCS (control) or no particles (PBS) and growth and survival monitored. (c) Tumour volumes in the AAV2-GB group were significantly reduced (p < 0.03) when compared with the AAV2-BB administered control group and the untreated group. (d) Animal survival in the AAV2-GB group was significantly (p = 0.036) increased when compared with the AAV2-MCS injected control group and the untreated group. (e-f) Immunological memory following tumour treatment. (e) 'JBS cured' mice (those that had regression of JBS tumour) received a tumourogenic dose of JBS cells on the opposite flank to the original, 'cured' JBS tumour. 100% cured animals receiving JBS displayed no tumour growth, while 0% of JBS naïve controls survived beyond 30 days. (f) In vivo cytotoxicity assay. Mice received injections of a mixture of JBS cells and splenocytes from either AAV2-GB 'cured' mice or naïve mice. All mice receiving splenocytes from 'cured' mice failed to grow tumours, while JBS tumours developed in all control animals receiving splenocytes from naïve mice. (* Statistical significance (p < 0.05))

Back to article page